Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Overview Bruton’s tyrosine kinase (BTK) Inhibitors are non-receptor tyrosine kinase inhibitors which regulates the B-cell’s signaling, proliferation, growth and differentiation by targeting B-cell receptors. Bruton’s tyrosine kinase (BTK) Inhibitors is deliberated to treat B-cell leukemia, lymphomas, haematological malignancies and graft versus host disease (GVDH). Imbruvica (ibrutinib) is an approved …
Continue reading “Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Set for Rapid Growth by 2030”